As FcγRIIB is expressed on all circulating CD20+ B lymphocytes, not just lymphoma cells, restricting the function of the FcγRIIB mAb to the TME via conditional blocking/activation may help to reduce off‐target and sink effects. The gene discussed is FCGR2B; the disease is lymphoma.